A federal judge in Virginia has ruled that the FDA's restrictions on mifepristone are arbitrary and without scientific merit, ordering the Trump administration to reconsider whether the limits should remain in place.
Judge Robert S. Ballou found that prior FDA reviews have consistently determined mifepristone to be safe and effective, yet the agency maintains regulatory barriers that serve no medical purpose. The decision came in the case Whole Woman's Health Alliance v FDA, filed in May 2023 by the Center for Reproductive Rights on behalf of abortion providers in Virginia, Kansas, and Montana.
The plaintiffs challenged three specific restrictions. One requires providers and pharmacies to complete special registration and certification procedures. Another mandates that patients sign paperwork the providers describe as duplicative, inaccurate, and confusing. A third limits mail distribution and pharmacy access to the medication.
"These regulations serve no medical purpose," said Amy Hagstrom Miller, president and CEO of Whole Woman's Health Alliance, noting that her clinic has struggled to serve growing numbers of patients traveling from states with abortion bans. Kathryn Boyd, president and CEO of Trust Women in Kansas, said that removing barriers would mean "fewer delays, less stress and more dignity for our patients."
Mifepristone now accounts for nearly two-thirds of all abortions performed in the United States. Research spanning a quarter-century has documented the drug's safety and effectiveness.
The ruling complicates a separate legal battle unfolding in the Fifth Circuit Court of Appeals. Louisiana has asked the FDA to reinstate stricter regulations that would ban mail-order mifepristone and impose additional limits on pharmacy prescriptions. The case will test how the current administration handles competing pressures from conservative lawmakers and advocates seeking tighter controls versus courts finding those controls medically baseless.
The FDA currently lacks a permanent commissioner and is undertaking a review of abortion pill regulations that conservative lawmakers and activists have pushed the agency to tighten.
Nancy Northup, president and CEO of the Center for Reproductive Rights, framed the ruling as a victory for science over ideology. "The efforts to restrict it are not about science or safety," she said in a statement. "They are about making abortion harder to access."
Author James Rodriguez: "Judge Ballou's decision puts real pressure on an administration that promised to side with abortion restrictions, forcing it to justify rules the bench says lack any scientific foundation."
Comments